SELLAS Life Sciences Group
Open
$4.97
Prev. Close
$4.97
High
$4.98
Low
$4.93
Market Snapshot
$665.21M
-24.8
-0.52
13
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
emptyResult
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Recently from Cashu
SELLAS Life Sciences Group: Pioneering Innovative Cancer Immunotherapy and Transforming Treatment Paradigms
SELLAS Life Sciences Group: Innovating Cancer Immunotherapy SELLAS Life Sciences Group Inc. is at the forefront of developing innovative cancer immunotherapies, directing its efforts towards creating…
SLS City-Stage Activations Offer Patient Outreach Playbook for SELLAS Life Sciences Group
City-Stage Skateboarding Offers a Playbook for Biotech Patient Outreach Street League Skateboarding’s move to combine stadium shows with public “Spot Takeover” activations is creating a model that hea…
SLS Playa Mujeres Introduces Kosher Dining Program to Enhance Guest Experience
SLS Playa Mujeres Launches Kosher Dining Program to Cater to Diverse Guest Needs SLS Playa Mujeres, an upscale all-inclusive resort located just north of Cancun, Mexico, announces the introduction of…
Please provide the content you want summarized, and I'll create a title for you.
Sure! Please provide the text you'd like summarized, and I'll create a 300-word paragraph for you.